EMA grants CEL-SCI waiver ‘clearing’ marketing authorization path for Multikine

CEL-SCI announced that the European Medicines Agency EMA Paediatric Committee granted CEL-SCI a product-specific waiver of strict requirements for commercialization of cancer drugs in the European Union EU . “The granting of a paediatric investigation plan waiver by the EMA’s Paediatric Committee is a big step forward for Multikine, because it is one less hurdle that we face on our path towards commercialization in Europe, which could have greatly delayed our plans in the EU had the waiver not been granted,” said Geert Kersten, CEO of CEL-SCI. “We are moving forward in multiple countries and regulatory jurisdictions at the same time, including not only the US and Europe but also the United Kingdom and Canada.”